VNRX vs. TKNO, ABIO, AWH, ICCC, OCX, ACHV, YS, CGTX, CNTB, and ATHA
Should you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Alpha Teknova (TKNO), ARCA biopharma (ABIO), Aspira Women's Health (AWH), ImmuCell (ICCC), OncoCyte (OCX), Achieve Life Sciences (ACHV), YS Biopharma (YS), Cognition Therapeutics (CGTX), Connect Biopharma (CNTB), and Athira Pharma (ATHA). These companies are all part of the "medical" sector.
Alpha Teknova (NASDAQ:TKNO) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.
VolitionRx has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alpha Teknova had 2 more articles in the media than VolitionRx. MarketBeat recorded 3 mentions for Alpha Teknova and 1 mentions for VolitionRx. Alpha Teknova's average media sentiment score of 0.59 beat VolitionRx's score of 0.00 indicating that VolitionRx is being referred to more favorably in the news media.
VolitionRx has a consensus target price of $2.50, indicating a potential upside of 237.38%. Given Alpha Teknova's stronger consensus rating and higher probable upside, analysts clearly believe VolitionRx is more favorable than Alpha Teknova.
Alpha Teknova has a net margin of -100.26% compared to Alpha Teknova's net margin of -4,557.29%. Alpha Teknova's return on equity of 0.00% beat VolitionRx's return on equity.
Alpha Teknova received 3 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 30.00% of users gave Alpha Teknova an outperform vote while only 27.27% of users gave VolitionRx an outperform vote.
Alpha Teknova has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.
13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 8.1% of VolitionRx shares are held by institutional investors. 15.2% of Alpha Teknova shares are held by insiders. Comparatively, 15.4% of VolitionRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
VolitionRx beats Alpha Teknova on 11 of the 18 factors compared between the two stocks.
Get VolitionRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VolitionRx Competitors List
Related Companies and Tools
